August 5, 2015Open Access

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Sweeney et al. (Wed,) studied this question.

synapsesocial.com/papers/69d76c47db9d5e1bf4b8a53d https://doi.org/https://doi.org/10.1056/nejmoa1503747

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Enzalutamide in Metastatic Prostate Cancer before Chemotherapy2014 · 3,038 citations
2Nonparametric Estimation from Incomplete Observations1958 · 7,765 citations
3Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate2002 · 3,203 citations
4Nonparametric Estimation from Incomplete Observations1992 · 45,550 citations
5Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial2013 · 740 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo